Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
9/29/23 | AbbVie (ABBV) | Venclexta for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
9/27/23 | BrainStorm (BCLI) | NurOwn for Amyotrophic Lateral Sclerosis (ALS) | Subscribers Only | Subscribers Only | Subscribers Only |
9/25/23 | BrainStorm (BCLI) | NurOwn for Amyotrophic Lateral Sclerosis (ALS) | Subscribers Only | Subscribers Only | Subscribers Only |
9/23/23 | 4SC (VSC) | Resminostat for Cutaneous T-Cell Lymphoma (CTCL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
9/22/23 | Astellas Pharma (4503:JP) | Padcev for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/30/23 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion |
09/30/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
09/30/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation (Emerging Markets) |
09/30/23 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
09/30/23 | Subscribers Only | Subscribers Only | Trial Announcement - Patient Enrollment Completed |